Zai Lab Limited (NASDAQ:ZLAB) Q2 2020 Earnings Conference Call August 13, 2020 8:00 AM ET Company Participants Billy Cho – Chief Financial Officer Samantha Du – Founder, Chair Person and Chief Executive Officer Tao Fu – President and Chief Operating Officer Jonathan Wang – Head-Business Development Conference Call Participants Yigal Nochomovitz – Citi Group Anupam Rama – J.P. Morgan Jonathan Chang – SVB Leerink Maury Raycroft – Jefferies Seamus Fernandez – Guggenheim Wilfred Yuen – BOCI Ziyi Chen – Goldman ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Zai Lab Limited (NASDAQ:ZLAB) Q4 2019 Earnings Conference Call March 19, 2020 8:30 AM ET Company Participants Billy Cho – Chief Financial Officer Samantha Du – Founder and Chief Executive Officer Tao Fu – President and Chief Operating Officer Jonathan Wang – Head-Business Development Valeria Fantin – Chief Scientific Officer Conference Call Participants Yigal Nochomovitz – Citigroup Anupam Rama – JPMorgan Jonathan Chang – SVB Leerink Maury Raycroft – Jefferies Yang Huang – Bank of America Xiang Gao – Macqua ...

Zai Lab Limited (NASDAQ:ZLAB) Q2 2019 Earnings Conference Call September 3, 2019 8:30 AM ET Company Participants Jonathan Wang - Senior VP & Head of Business Development Ki Chul Cho - CFO Tao Fu - President, COO & Director Yi Liang - Chief Commercial Officer & President of Greater China Ying Du - Founder, Chairman & CEO Conference Call Participants Yigal Nochomovitz - Citigroup Anupam Rama - JPMorgan Maurice Raycroft - Jefferies David Ruch - SVB Leerink Serena Shao - Credit Suisse Yang Huang - Bank of Ameri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Financial Data and Key Metrics Changes - As of December 31, 2018, cash and cash equivalents and short-term investments totaled $263.3 million, including net proceeds from a follow-on offering in September 2018 [26] - R&D expenses increased to $120.3 million for the year ended December 31, 2018, compared to $39.3 million for the same period in 2017, primarily due to increased upfront licensing fees and ongoing clinical trials [26] - SG&A expenses rose to $21.6 million for the year ended December 31, 2018, up from $12.0 million in 2017, driven by increased payroll and headcount [26] - The net loss for the year was $139.1 million, or $2.64 per share, compared to a net loss of $50.4 million, or $2.32 per share for the previous year [26] Business Line Data and Key Metrics Changes - The company has seven late-stage programs, three of which are U.S. FDA approved: Niraparib, Optune, and Omadacycline [9] - Niraparib, branded as Zejula, is positioned as a best-in-class PARP inhibitor for ovarian cancer and other solid tumors, with an NDA submitted for priority review in China [16][17] - Optune is marketed in the U.S., EU, and Japan for glioblastoma and has shown clinical proof of concept in multiple tumor types [20] Market Data and Key Metrics Changes - The company anticipates launching Niraparib in China in the second half of 2019, which is over a year ahead of initial expectations [17] - The company has built a commercial infrastructure in Mainland China, with over 180 employees dedicated to R&D and commercial operations [10][25] Company Strategy and Development Direction - Zai Lab aims to address significant unmet medical needs with a pipeline focused on first-in-class or best-in-class products [9] - The company plans to continue expanding its oncology portfolio and has established a U.S. headquarters to enhance its discovery and business development capabilities [11] - The strategic theme includes building strongholds in women's cancer, GI cancers, and glioma, with multiple synergistic assets in each area [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for Niraparib and Optune to gain reimbursement in China, highlighting the importance of being included in the national reimbursement list [73][74] - The company is confident in its ability to manage commercial operations regardless of reimbursement outcomes, leveraging experience in provincial reimbursement processes [74] - Management noted that innovative oncology drugs have been performing well in China, which bodes well for upcoming product launches [35] Other Important Information - The company has strengthened its executive team, including the appointment of Tao Fu as President and COO, and Dr. Yong-Jiang Hei as Chief Medical Officer for Oncology [12][13] - Zai Lab has established partnerships with several companies, adding six assets through four major strategic partnerships in 2018 [11] Q&A Session Summary Question: Metrics for tracking Zejula and Optune launches in China - Management indicated they will track non-revenue KPIs such as reach to targeted physicians and listing status [31] Question: Recent oncology launches in China - Management referenced the successful launch of Tagrisso, which achieved nearly $150 million in its first year [34] Question: Approval status for Niraparib - Management confirmed that the priority review for Niraparib is a full approval, and they expect to launch in the second half of 2019 [36][38] Question: Pricing strategy for Optune and Niraparib - Management is still formulating pricing strategies but indicated a potential 30% discount to U.S. prices for Niraparib [77] Question: Timeline for first-line ovarian cancer approval - Management expects to leverage data from the PRIMA study for NDA submission in China, with readouts anticipated in the second half of 2019 [78]